Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369395 · ClinicalTrials.gov registry record · Phase 2
A Study of Volociximab in Metastatic Melanoma
A Phase 2 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00369395 is a Phase 2 study that was terminated before completion, run by Abbott. The registered enrollment target is 19 participants.
The verdict
NCT00369395, a Phase 2 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter, research study determining the effects of an investigational drug called volociximab in metastatic melanoma. The purpose of the study is to compare the clinical benefit and safety of volociximab. Pharmacokinetics and mechanism of action will also be evaluated.
Interventions
- DRUG volociximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369395
The ClinicalTrials.gov registry entry for NCT00369395 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which volociximab is the first listed.
NCT00369395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369395 about?
NCT00369395 is a clinical study titled "A Study of Volociximab in Metastatic Melanoma". This is a Phase 2, multicenter, research study determining the effects of an investigational drug called volociximab in metastatic melanoma. The purpose of the study is to compare the clinical benefit and safety of volociximab. Pharmacokinetics and mechanism of action will also be evaluated.
What is the current status of trial NCT00369395?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2006-12. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00369395?
The interventions under investigation include: volociximab (DRUG).
Who is sponsoring clinical trial NCT00369395?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.